×
About 17,847 results

ALLMedicine™ Neutropenia Center

Research & Reviews  8,419 results

Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel ad...
https://doi.org/10.1007/s00280-020-04140-x
Cancer Chemotherapy and Pharmacology; Tsushima T, Kasai H et. al.

Sep 15th, 2020 - To develop a pharmacokinetic (PK) and pharmacodynamic (PD) model for neutropenia following nab-paclitaxel administration and identify factors associated with drug disposition and changes in neutrophil counts in patients with solid cancer. PK/PD an...

Rash and neutropenia after the administration of oxaliplatin and 5-fluorouracil plus ca...
https://doi.org/10.21037/apm-20-1321
Annals of Palliative Medicine; Huang J, Jiang C et. al.

Sep 14th, 2020 - A 56-year-old male patient was admitted due to a "rectal malignant tumor". He suffered from rash and neutropenia after multiple chemotherapy sessions including oxaliplatin, 5-fluorouracil (5- FU), and calcium folinate injection (CF) which are call...

A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, a...
https://doi.org/10.1007/s10147-020-01768-w
International Journal of Clinical Oncology; Tamura S, Taniguchi H et. al.

Sep 14th, 2020 - For unresectable or recurrent advanced gastric adenocarcinoma (AGC), tri-weekly administration of nanoparticle albumin-bound paclitaxel (nab-PTX) at 260 mg/m2 achieved a response rate of 27.8% in a phase II trial in Japan. However, frequent neutro...

Comparison of Different Doses of Granulocyte Colony-stimulating Factor in the Treatment...
https://doi.org/10.1097/MPH.0000000000001940
Journal of Pediatric Hematology/oncology; Ok ZO, Kupeli S et. al.

Sep 14th, 2020 - Febrile neutropenia (FEN) is a significant side effect after chemotherapy, and it is known that using granulocyte colony-stimulating factor (G-CSF) has positive effects on treatment results. In this study, the effects of different G-CSF doses (5 t...

Hematologic presentation and the role of untargeted metabolomics analysis in monitoring...
https://doi.org/10.1002/ajmg.a.61851
American Journal of Medical Genetics. Part A REFERENCES; Pillai NR, Amin H et. al.

Sep 10th, 2020 - Riboflavin transporter deficiency (RTD) (MIM #614707) is a neurogenetic disorder with its most common manifestations including sensorineural hearing loss, peripheral neuropathy, respiratory insufficiency, and bulbar palsy. Here, we present a 2-yea...

see more →

Guidelines  53 results

Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by t...
https://www.idsociety.org/globalassets/idsa/practice-guidelines/2019-asymptomatic-bacteriuria.pdf

Mar 20th, 2019 - Asymptomatic bacteriuria (ASB) is a common finding in many populations, including healthy women and persons with underlying urologic abnormalities. The 2005 guideline from the Infectious Diseases Society of America recommended that ASB should be s.

ACR Appropriateness Criteria® Acute Nonlocalized Abdominal Pain.
https://doi.org/10.1016/j.jacr.2018.09.010
Journal of the American College of Radiology : JACR; , Scheirey CD et. al.

Nov 5th, 2018 - The range of pathology in adults that can produce abdominal pain is broad and necessitates an imaging approach to evaluate many different organ systems. Although localizing pain prompts directed imaging/management, clinical presentations may vary ...

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
http://ascopubs.org/doi/full/10.1200/JCO.18.00374
Taplitz,R.,et al

Sep 3rd, 2018 - Antibacterial and antifungal prophylaxis is recommended for patients who are at high risk of infection, including patients who are expected to have profound, protracted neutropenia, which is defined as < 100 neutrophils/µL for > 7 days or other ri...

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
http://ascopubs.org/doi/full/10.1200/JCO.2017.77.6211
Randy A. Taplitz

May 9th, 2018 - To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer.

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: Americ...
https://doi.org/10.1200/JCO.2017.77.6211
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Taplitz RA, Kennedy EB et. al.

Feb 20th, 2018 - Purpose To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer. Methods ASCO and IDSA convened an Update Expert Panel and conducted a syst...

see more →

Drugs  233 results see all →

Clinicaltrials.gov  8,827 results

Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel ad...
https://doi.org/10.1007/s00280-020-04140-x
Cancer Chemotherapy and Pharmacology; Tsushima T, Kasai H et. al.

Sep 15th, 2020 - To develop a pharmacokinetic (PK) and pharmacodynamic (PD) model for neutropenia following nab-paclitaxel administration and identify factors associated with drug disposition and changes in neutrophil counts in patients with solid cancer. PK/PD an...

Rash and neutropenia after the administration of oxaliplatin and 5-fluorouracil plus ca...
https://doi.org/10.21037/apm-20-1321
Annals of Palliative Medicine; Huang J, Jiang C et. al.

Sep 14th, 2020 - A 56-year-old male patient was admitted due to a "rectal malignant tumor". He suffered from rash and neutropenia after multiple chemotherapy sessions including oxaliplatin, 5-fluorouracil (5- FU), and calcium folinate injection (CF) which are call...

A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, a...
https://doi.org/10.1007/s10147-020-01768-w
International Journal of Clinical Oncology; Tamura S, Taniguchi H et. al.

Sep 14th, 2020 - For unresectable or recurrent advanced gastric adenocarcinoma (AGC), tri-weekly administration of nanoparticle albumin-bound paclitaxel (nab-PTX) at 260 mg/m2 achieved a response rate of 27.8% in a phase II trial in Japan. However, frequent neutro...

Comparison of Different Doses of Granulocyte Colony-stimulating Factor in the Treatment...
https://doi.org/10.1097/MPH.0000000000001940
Journal of Pediatric Hematology/oncology; Ok ZO, Kupeli S et. al.

Sep 14th, 2020 - Febrile neutropenia (FEN) is a significant side effect after chemotherapy, and it is known that using granulocyte colony-stimulating factor (G-CSF) has positive effects on treatment results. In this study, the effects of different G-CSF doses (5 t...

Hematologic presentation and the role of untargeted metabolomics analysis in monitoring...
https://doi.org/10.1002/ajmg.a.61851
American Journal of Medical Genetics. Part A REFERENCES; Pillai NR, Amin H et. al.

Sep 10th, 2020 - Riboflavin transporter deficiency (RTD) (MIM #614707) is a neurogenetic disorder with its most common manifestations including sensorineural hearing loss, peripheral neuropathy, respiratory insufficiency, and bulbar palsy. Here, we present a 2-yea...

see more →

News  315 results

FDA grants accelerated approval for Immunomedics' breast cancer therapy
https://www.reuters.com/article/us-immunomedics-fda/fda-grants-accelerated-approval-for-immunomedics-breast-cancer-therapy-idUSKCN2242NT

Apr 22nd, 2020 - (Reuters) - Immunomedics Inc won an accelerated approval from the U.S. Food and Drug Administration for Trodelvy, its therapy for a form of invasive breast cancer that has worsened despite two prior rounds of treatment, the company said on Wednesd...

Cabazitaxel Improves Progression-Free and Overall Survival in Metastatic Prostate Cancer After Progression on Abiraterone or Enzalutamide
https://www.mdedge.com/jcomjournal/article/219674/oncology/cabazitaxel-improves-progression-free-and-overall-survival/page/0/2?channel=246

Mar 27th, 2020 - The adverse events of grade 3 or greater occurring in the cabazitaxel group should be discussed with patients, including fatigue, diarrhea, peripheral neuropathy, and febrile neutropenia. The data from the CARD trial provide guidance regarding the.

‘Simple’ model predicts severe neutropenia risk in lung cancer patients
https://www.mdedge.com/chestphysician/article/215676/lung-cancer/simple-model-predicts-severe-neutropenia-risk-lung-cancer?channel=39313
Andrew D. Bowser, MDedge News

Jan 16th, 2020 - A new and simple model for predicting risk of severe neutropenia in advanced lung cancer could ease the evaluation process and help inform patient management decisions, according to investigators. The model, based on 10 pretreatment variables, app.

FDA approves Ziextenzo for neutropenia-related infection reduction
https://www.mdedge.com/hematology-oncology/article/211656/patient-survivor-care/fda-approves-ziextenzo-neutropenia-related?channel=39313
Lucas Franki

Nov 5th, 2019 - The Food and Drug Administration has approved the biosimilar Ziextenzo (pegfilgrastim-bmez) to reduce the incidence of infection in patients with nonmyeloid cancer receiving suppressive anticancer drugs that are associated with febrile neutropenia.

AUGMENT: Lenalidomide/Rituximab vs Placebo/Rituximab in Relapsed or Refractory Indolent Lymphoma
https://www.mdedge.com/jcomjournal/article/208643/hematology/augment-lenalidomide/rituximab-vs-placebo/rituximab-relapsed/page/0/4?channel=325

Oct 7th, 2019 - In the R2 arm of this study, 55% patients experienced grades 3 and 4 neutropenia. With a median age of presentation for both follicular lymphoma and MZL of over 60 years, oncologists should remain aware of this potentially fatal complication, espe.

see more →